Cargando…

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options

Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70% chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients are refractory or relapsing. Many attempts failed to improve the outcome of DLBCL patients, including the intensification of R-CHOP regi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vodicka, Prokop, Klener, Pavel, Trneny, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739046/ https://www.ncbi.nlm.nih.gov/pubmed/36510607 http://dx.doi.org/10.2147/OTT.S326632

Ejemplares similares

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma (DLBCL) in an Aged Raccoon (Procyon lotor)
por: D’Annunzio, Giulia, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion. Close resemblance of its clinicopathological features to intravascular large B-cell lymphoma, but not to DLBCL-not otherwise specified
por: Itami, Hiroe, et al.
Publicado: (2021)

Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience
por: Polgárová, Kamila, et al.
Publicado: (2022)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
por: Griffiths, Robert, et al.
Publicado: (2010)

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2022)

Retracted: Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Markers, Disease
Publicado: (2023)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL)
por: Markovic, O., et al.
Publicado: (2012)

Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL)
por: Feng, Pengcheng, et al.
Publicado: (2021)

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
por: Regier, Dean A., et al.
Publicado: (2022)

SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients
por: Schif, Birgit, et al.
Publicado: (2012)

The fear of lymphadenopathy: A cautionary case of sarcoidosis masquerading as recurrent diffuse large b-cell lymphoma (DLBCL)
por: Whooley, Peter D., et al.
Publicado: (2018)

P1268: DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
por: Jiang, Y., et al.
Publicado: (2022)

Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma
por: Wang, Sophia S, et al.
Publicado: (2008)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
por: Dunleavy, K, et al.
Publicado: (2009)

The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy
por: Coughlan, Monica, et al.
Publicado: (2014)

Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling
por: Greenbaum, Adam M., et al.
Publicado: (2022)

Extra- and Intracranial Diffuse Large B-Cell Lymphoma (DLBCL) Mimicking Meningioma: A Case Report and Literature Review
por: Matejka, Matthias, et al.
Publicado: (2023)

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL
por: Bhalla, Kavita, et al.
Publicado: (2018)

Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy
por: Klimiuk, Paweł, et al.
Publicado: (2021)

Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China
por: Sun, Jian-Jun, et al.
Publicado: (2020)

Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis
por: Tsutsué, Saaya, et al.
Publicado: (2022)

PB2152: BIOLOGICAL AND CLINICAL CORRELATES OF GALECTIN-3 (GAL-3) EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Basic-Kinda, S., et al.
Publicado: (2022)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

New treatment options in elderly patients with Diffuse Large B-cell Lymphoma
por: Arcari, Annalisa, et al.
Publicado: (2023)

Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report
por: Klanova, Magdalena, et al.
Publicado: (2012)

Prevalence of Anti-Citrullinated Protein Antibodies (ACPA) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Case-Control Study
por: Assmann, Gunter, et al.
Publicado: (2014)

A Multi-institutional Analysis of Diffuse Large B-cell Lymphoma (DLBCL) Treated with Consolidative Radiotherapy and the Impact of Cell-of-origin on Outcomes
por: Rajasooriyar, Chrishanthi, et al.
Publicado: (2019)

Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database
por: Zhou, Chunhui, et al.
Publicado: (2021)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Illidge, T., et al.
Publicado: (2022)

A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy
por: Wang, Ping, et al.
Publicado: (2023)

PB2293: REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER’S EXPERIENCE
por: De Ascanio, Victoria Ramos, et al.
Publicado: (2023)

PB2376: ASSAY DEVELOPMENT AND VALIDATION OF IG-HTS TO MONITOR MRD IN PLASMA OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Wu, Jinghua, et al.
Publicado: (2023)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

Author Correction: Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL
por: Bhalla, Kavita, et al.
Publicado: (2018)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (DLBCL NOS) Presenting as Multiple Subcutaneous Nodules: An Unusual Cutaneous Presentation of Systemic Disease
por: Tavberidze, Nika, et al.
Publicado: (2023)

The expression of hypoxia inducible factor-1 alpha in diffuse large B-cell lymphoma (DLBCL) patients: a cross-sectional study in Indonesia
por: Pangarsa, Eko Adhi, et al.
Publicado: (2023)

P1158: REAL-WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND TREATMENT OUTCOMES OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) BY LINE OF THERAPY (LOT)
por: Sineshaw, Helmneh, et al.
Publicado: (2023)

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas
por: Klanova, Magdalena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0du4j2cvlqmoj78ldtto4k1qsv